BRPI0519602A2 - derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento - Google Patents

derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento

Info

Publication number
BRPI0519602A2
BRPI0519602A2 BRPI0519602-7A BRPI0519602A BRPI0519602A2 BR PI0519602 A2 BRPI0519602 A2 BR PI0519602A2 BR PI0519602 A BRPI0519602 A BR PI0519602A BR PI0519602 A2 BRPI0519602 A2 BR PI0519602A2
Authority
BR
Brazil
Prior art keywords
medicament
tetrahydroquinoline derivatives
cycloalkyl substituted
prevention
preparation
Prior art date
Application number
BRPI0519602-7A
Other languages
English (en)
Inventor
Heike Gielen-Haertwig
Alexandros Vakolopoulus
Olaf Weber
Martina Wuttke
Hilmar Bischoff
Volkhart Li
Carsten Schmeck
Michael Thutewohl
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of BRPI0519602A2 publication Critical patent/BRPI0519602A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

DERIVADOS DE TETRAHIDROQUINOLINA SUBSTITUÍDOS COM 4-CICLOALQUILA E SEU USO COMO MEDICAMENTO. A presente invenção refere-se a um novo derivado de tetrahidro-quinolina, a um processo para sua preparação, ao seu uso sozinho ou em combinações para o tratamento e/ou prevenção de doenças, bem como ao seu uso para preparação de medicamentos particularmente como inibidor da proteína de transferência de éster de colesterol (CETP) para o tratamento e/ou prevenção de doenças cardiovasculares, particularmente de hipolipo-proteinemias, dislipidemias, hipertrigliceridemias, hiperlipidemias, hipercoles-terolemias e arteriosclerose.
BRPI0519602-7A 2004-12-18 2005-12-15 derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento BRPI0519602A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
PCT/EP2005/013490 WO2006063828A1 (de) 2004-12-18 2005-12-15 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente

Publications (1)

Publication Number Publication Date
BRPI0519602A2 true BRPI0519602A2 (pt) 2009-02-25

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519602-7A BRPI0519602A2 (pt) 2004-12-18 2005-12-15 derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento

Country Status (27)

Country Link
US (2) US8124775B2 (pt)
EP (1) EP1828137B1 (pt)
JP (1) JP5132317B2 (pt)
KR (1) KR20070090248A (pt)
AR (1) AR055011A1 (pt)
AT (1) ATE555097T1 (pt)
AU (1) AU2005315770B2 (pt)
BR (1) BRPI0519602A2 (pt)
CA (1) CA2591397A1 (pt)
CU (1) CU23452B7 (pt)
CY (1) CY1112887T1 (pt)
DK (1) DK1828137T3 (pt)
DO (1) DOP2005000259A (pt)
ES (1) ES2384980T3 (pt)
GT (1) GT200500377A (pt)
IL (1) IL184008A (pt)
MA (1) MA29100B1 (pt)
MX (1) MX2007007188A (pt)
NO (1) NO20073146L (pt)
PE (1) PE20060767A1 (pt)
PL (1) PL1828137T3 (pt)
PT (1) PT1828137E (pt)
RU (1) RU2393151C2 (pt)
SI (1) SI1828137T1 (pt)
TW (1) TW200635900A (pt)
UY (1) UY29276A1 (pt)
WO (1) WO2006063828A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828136A1 (de) * 2004-12-18 2007-09-05 Bayer HealthCare AG (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
EP2268644B1 (en) 2008-03-05 2011-08-17 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
PE20121743A1 (es) 2010-02-19 2012-12-22 Boehringer Ingelheim Int Derivados de piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su preparacion
NZ606100A (en) * 2010-07-09 2014-08-29 Daiichi Sankyo Co Ltd Substituted pyridine compound
EP2675811A1 (en) 2011-02-17 2013-12-25 Boehringer Ingelheim International GmbH Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
EP2760868B1 (en) 2011-08-17 2018-04-25 Boehringer Ingelheim International GmbH Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation
EP2801574B1 (en) * 2012-01-06 2016-07-27 Daiichi Sankyo Company, Limited Acid adduct salts of substituted pyridine compound as cholesteryl ester transfer protein (cetp) inhibitors
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19704244A1 (de) * 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) * 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
EP1828136A1 (de) * 2004-12-18 2007-09-05 Bayer HealthCare AG (5s)-3-[(s)-fluor(4-trifluoromethylphenyl)methyl]-5,6,7,8-tetrahydrochinolin-5-ol derivate und ihre verwendung als cetp-inhibitoren

Also Published As

Publication number Publication date
UY29276A1 (es) 2006-07-31
US20120142728A1 (en) 2012-06-07
RU2007127127A (ru) 2009-01-27
EP1828137A1 (de) 2007-09-05
PL1828137T3 (pl) 2012-09-28
CU23452B7 (es) 2009-12-01
CY1112887T1 (el) 2016-04-13
PE20060767A1 (es) 2006-09-10
PT1828137E (pt) 2012-07-04
IL184008A0 (en) 2007-10-31
ATE555097T1 (de) 2012-05-15
GT200500377A (es) 2006-11-09
US8124775B2 (en) 2012-02-28
AU2005315770B2 (en) 2011-12-08
TW200635900A (en) 2006-10-16
MX2007007188A (es) 2007-08-14
NO20073146L (no) 2007-09-18
DK1828137T3 (da) 2012-07-23
MA29100B1 (fr) 2007-12-03
CA2591397A1 (en) 2006-06-22
RU2393151C2 (ru) 2010-06-27
AR055011A1 (es) 2007-08-01
KR20070090248A (ko) 2007-09-05
US20080255068A1 (en) 2008-10-16
IL184008A (en) 2012-03-29
JP5132317B2 (ja) 2013-01-30
DOP2005000259A (es) 2006-11-15
WO2006063828A1 (de) 2006-06-22
AU2005315770A1 (en) 2006-06-22
ES2384980T3 (es) 2012-07-16
JP2008524145A (ja) 2008-07-10
EP1828137B1 (de) 2012-04-25
SI1828137T1 (sl) 2012-08-31

Similar Documents

Publication Publication Date Title
BRPI0519602A2 (pt) derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento
BRPI0519566A2 (pt) derivados de (5s)-3-[(s)-fléor(4-trifluormetilfenil)metil]-5,6,7,8-tet raidroquinolin-5-ol e seu uso como inibidores de cetp
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
BRPI0516842A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta agonistas e uso desses compostos
BRPI0821027B8 (pt) 4-(4-ciano-2-tioaril)di-hidropirimidinonas para tratamento e/ou prevenção de lesões do pulmão e do sistema cardiovascular, seu processo de preparação e seu uso, e medicamento
BR0209774A (pt) Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento
BR0110486A (pt) Antranilamidas e sua aplicação como medicamento
BR0316264A (pt) Medicamento para tratamento de doença pulmonar obstrutiva crÈnica
BR0209957A (pt) Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
BRPI0817262A2 (pt) Compostos derivados de biaril sulfonamida, composições farmacêuticas que os contêm, processo para sua fabricação, método e usos para o tratamento terapêutico e/ou profilático de doenças e usos na preparação de medicamentos
BRPI0416801A (pt) derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
BR0307294A (pt) ésteres de ácido fluorenocarboxìlico, processo para sua preparação bem como seu uso como medicamento
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BR112014018378A8 (pt) Processo contínuo para a preparação de um comprimido compreendendo ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
BR9915553A (pt) Amidas de ácido antranìlico e seu emprego como medicamento
BRPI0507622A (pt) composto baseado em ácido hialurÈnico, sal de sódio, processo para preparar um composto ou um seu sal, composição farmacêutica, produto medicinal e dispositivo médico para uso humano ou veterinário, e, uso de composto ou de seu sal
BRPI0911273B8 (pt) composição farmacêutica compreendendo um inibidor de dpp-iv, bem como processo para sua preparação
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0607583A2 (pt) derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
BRPI0519620A2 (pt) compostos, processo para a sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento terapÊutico e/ou profilÁtico de enfermidades que sço moduladas por agonistas alfa-lxr e/ou beta-lxr e utilizaÇço desses compostos
BRPI0507375A (pt) derivados de 1h-tieno[2,3-c]pirazol úteis como inibidores de quinase
GB0620385D0 (en) Novel compounds
BRPI0607614A2 (pt) sal de besilato da 7-(2-(4-3-trifluorometil-fenil)-1,2,3,6-tetrahidropirid- 1-il)etil) isoquinoleìna, o respectivo medicamento, composição farmacêutica e uso
BRPI0517327A (pt) derivados de pirimidina e seu uso como moduladores ppar-alfa

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: TRANSFERIDO POR FUSAO DE: BAYER HEALTHCARE AG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2284 DE 14/10/2014.